AdAlta has changed the structure of its lead therapy candidate for AD-114, for the treatment of pulmonary fibrosis. The new product, renamed AD-214, has enhanced activity and improved stability compared to AD-114, allowing a better outcome, according to AdAlta. AD-214 retains key features of its precursor, as it…
Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) may share a common disease mechanism — degradation of elastin in the lungs — suggesting its potential as a biomarker for both diseases, research shows. The study, “Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis,”…
When most of us think about going on vacation, images of relaxation pop into our minds. The point of a vacation is to feel rejuvenated and to catch a break from our structured and routine-filled days of school, work, appointments, or errands. Planning a vacation should be fun…
BerGenBio’s bemcentinib (BGB324) stops the progression of aggressive tissue scarring in the lungs and liver, preclinical-trial research shows. Researchers published the findings in the American Journal of Respiratory and Critical Care Medicine. The article is titled “Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.” The results were also presented…
A gene called FOXF1 can inhibit the progression of idiopathic pulmonary fibrosis (IPF), according to scientists at the Cincinnati Children’s Hospital Medical Center. They reported that IPF patients’ lungs, as well as the lungs of mouse models of IPF, lack the gene in cells called myofibroblasts that play a…
It is so hard to get used to using supplemental oxygen. I still remember my shock and anger when told I would have to cart oxygen around whenever I moved about. I couldn’t believe it! I had a few choice words to say to my doctor…
A chemical found in certain types of vegetables displayed anti-tissue scarring activity in laboratory and mice lung-tissue experiments, a study reports. The results suggested that the chemical, sulforaphane, could be used to treat idiopathic pulmonary fibrosis, or IPF, researchers said. An article about the study, “Sulforaphane attenuates…
The U.S. Food and Drug Administration recently granted orphan drug status to Reviva Pharmaceuticals’ treatment candidate RP5063 for idiopathic pulmonary fibrosis (IPF). Reviva is now planning to launch Phase 2 studies testing RP5063 in both IPF and pulmonary arterial hypertension (PAH) patients. The FDA granted orphan…
April 7, 2016, is a date that will be etched in my memory for a very long time. It is the date of my idiopathic pulmonary fibrosis (IPF) diagnosis, which followed nine long months of fatigue, shortness of breath, and a dry cough that never seemed to subside.
A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…
Get regular updates to your inbox.
